Viruses that Infect Lymphocytes: EBV and HIV

Long term Host - Pathogen Relationships

Host immune defense consistently fail to clear a few viral infections, why?

Examine mechanisms pathogens use to evade immune defense
Contrasting host-pathogen relationships of two prototype chronic infections

*Epstein-Barr Virus (EBV)*

- Large DNA virus, e.g. herpesviruses
- Coevolved with host species over millions of years
- Genetically stable
- **Persist**s in host in latent pattern of viral gene expression in response to T cell surveillance

*Human immunodeficiency virus (HIV-1)*

- RNA retrovirus
- Recently introduced into humans
- Error-prone viral replication mechanisms resulting in “swarms” of distinct strains “quasispecies”
- **Overwhelms** host by escaping from immune surveillance
Host-pathogen relationships

Some mechanisms of avoiding immune surveillance

1. Avoid recognition by cytotoxic T cells
   - Viral strains evolve that avoid presentation by p-MHC: mutate amino acids
     - Anchor peptide to MHC
     - Recognized by T cells (immunodominant)
   - Block steps of antigen processing

2. Modification of the immune response
   - Release of anti-inflammatory cytokines, IL-10

3. Suppression of viral expression by virus latency
   - Change from productive to latent mode by selective pressure of immune response
Syndromes resulting from EBV infection

Age of host influences character of primary infection

• Primary infection with EBV in childhood usually subclinical

• 25-70 % of newly infected adolescents and adults develop infectious mononucleosis:
  • Fever
  • Lymphadenopathy
  • Pharyngitis
  • Transient heterophil antibodies
  • Activated CD8 cytotoxic anti EBV T cells (“atypical lymphocytosis”)
 Syndromes resulting from EBV infection

*EBV-driven neoplasms*

• Nasopharyngeal carcinoma, Gastric cancer subset

• B cell lymphomas:
  • Burkitt's Lymphoma
  • Immunoblastic lymphoma in immunosuppressed host
  • Subset of Hodgkin’s disease
**Stages of EBV infection**

**EBV is a B cell lymphotropic herpesvirus**

**Binding** EBV surface glycoprotein to CD21 (CR2)

- CD21 expressed on B cells as BCR co-receptor complex with CD19
- CD21 also expressed on some epithelial cells, accounting for tropism

**Triggers** T-independent polyclonal B cell activation Ig synthesis and B cell proliferation

**Results** in T-independent release of heterophil and other antibodies (Rheumatoid factor, cold agglutinins, ANA)

**EBV enters the cell** by receptor mediated endocytosis
Initially EBV replicates as a productive lytic infection

• IgM antibodies to Viral Capsid Antigens (VCA) and Early Antigens (EA) are found at clinical presentation, indicating lytic replication and persists for 1-2 months.

• IgG anti VCA appears at time of clinical presentation and persists lifelong-"standard EBV titre”

• Antibodies to EA Peak at 3-4 weeks; marker of more severe disease

• Lytically infected cells are largely eliminated by EBV-specific cytotoxic CD8 T cells (atypical lymphocytes), NK cells, interferon-mediated mechanisms and ADCC
By 3-6 weeks EBV enters latent stage in majority of remaining infected B cells

- Antibodies to latent EB Nuclear Antigens (EBNA's) appear 3-6 weeks after initial infection; last lifelong

- Virus evades cytotoxic response in latent form

- CD8 T cells *(atypical lymphocytes)* play a crucial role in maintaining latency and kill productively infected B cells

Failure of CD8 function
- Immunoblastic lymphoma
- Burkitt’s lymphoma
Latency: EBV is maintained in its latent infective cycle as a multicopy circular 172Kd ds plasmid minichromosome with replication linked to B cell proliferation

**9 Latent proteins:**
* Six nuclear antigens: EBNA1, 2, 3A, 3B, 3C, and EBNA leader protein (EBNA-LP)
* Three latent membrane proteins: LMP1, LMP2A, and LMP2B

EBNA1 binds to the EBV *ori*, initiating replication and also acting as a transcriptional enhancer

*EBNA1 contains a gly-ala repeat region that inhibits the ATP motor of the proteasome, impeding further insertion of EBNA1 into the proteasome, thus halting its degradation, a strategy for avoiding surveillance*
**B cell lymphoblastoid cell line (BLCL)**

BLCL can be derived from nearly everyone, *in vitro*

Express all latency genes, a pattern designated latency III,

BLCL phenotype high expression of:
B cell activation markers CD23, CD30, CD39, and CD70
Cellular adhesion molecules LFA1 (CD11a/18), LFA3 (CD58), and ICAM1; (CD54)

Because of the adhesion molecules these BLCLs grow in large clumps in tissue culture
Immunoblastic lymphomas

Develop in transplant recipients or other patients receiving T cell immunosuppressive therapies

• Resembles the BLCL phenotype
• Express all latency genes
• Start as multi-/polyclonal proliferations
• Withdrawal of immunosuppression results in regression
• Secondary transformation events may occur: monoclonal lymphoma
**Burkitt’s lymphomas**

Chronic immune system drive, e.g. by malaria implicated as cofactor, but no overt immune deficiency

- Exhibit a different gene expression pattern “latency I”
- Only abundant EBNA1 transcription is found
- Lymphoma cells display a distinct phenotype: CD10+ (CALLA) and CD77+ (BLA), but lack expression of activation and adhesion molecules
- In culture Burkitt tumor B cell lines grow as dispersed single cells
The T cell immune response to viruses often uses a very small number of different CD8 T cell clones directed to one or a few “immunodominant” peptides encoded by the viral genome, that are often presented by just one allelic type of an individual’s HLA molecules.
EBV infection results in nasopharyngeal carcinomas in Papua New Guinea and southern China

- HLA-A11 frequency: African 1.5%, Caucasian 6.9%
- HLA-A11-positive Caucasians nearly always respond to two immunodominant HLA-A*1101 epitopes of the nuclear antigen EBNA3B (EBNA4):
  - **IV** VTDFSVK 416 to 424
  - AVF DRKS DAK 399 to 408

In lowland Papua New Guinea and southern China, more than 50% of individuals carry the HLA-A*1101 allele

- EVB strains in these areas have a point A -> C mutation, which produces a Lys -- Thr (K -> T) change of 424, the P9 anchor (Frequency dependent selection)

*Loss of recognition of immunodominant epitope and ability to recognize EBV is a mechanism of escaping the CTL response implicated in neoplastic transformation*
Organization of HIV-1 Provirus

**LTR**
- Long Terminal Repeat
- Contains control regions that bind host transcription factors (NF-κB, N/C, Sp1, TBP)
- Required for the initiation of transcription
- Contains RNA trans-acting response element (TAR) that binds Tat

**gag**
- PRSS: Polyprotein processed by PR
- MA, matrix (p17)
- Undergoes myristylation that helps target Gag polyprotein to lipid raft, implicated in nuclear import of HIV-1 and nuclear localization of capsid (p24)

**pol**
- Polymerase
- Encodes a variety of viral enzymes, including PR (p16), RT, and RNase H (p66/51), and IN (p32) all processed by PR
- NC, nucleocapsid (p7)
- Zn finger: RNA binding protein p6
- Interacts with Vpr, contains IIB domain that binds TAR and participates in terminal steps of virion budding

**vif**
- Viral infectivity factor (p23)
- Overcomes inhibitory effects of uninfected host factor, yielding more stable RT complexes

**vpu**
- Viral protein U
- Promotes CD4 degradation and influences viral release

**env**
- gp160 envelope protein
- Cleaved in endoplasmic reticulum to gp120 (SU) and gp41 (TM)
- gp120 mediates CD4 and chemokine receptor binding, while gp41 mediates fusion
- Contains RNA response element (RRE) that binds Rev

**rev**
- Regulator of viral gene expression (p19)
- Simulates RRE, enhances viral RNA splicing and promotes nuclear export of incompletely spliced viral RNAs

**tat**
- Transcriptional activator (p14)
- Binds TAR
- In presence of host cyclin T1 and C/EBP, enhances RNA
- Promotes elongation of the viral DNA template

**Negative**
- Nef
- Effector (p24)
- Promotes down-regulation of surface CD4 and MHC I expression
- Blocks apoptosis
- Enhances virion infectivity
- Alters state of cellular activation
- Progression to disease slowed significantly in absence of Nef

**Size**
- 9kb

**Contains**
- 9 genes encoding 15 proteins

---

**HIV**
Early events of HIV- infection

Binding of envelope gp120 prompts p41 to project 3 fusion domains that harpoon the membrane, resulting in fusion.

Integration leads to either latent or transcriptionally active infection.
Host Response to HIV-1 infection

First Phase: CD8 T cell response of immune system controls initial destruction of memory/effectector CD4 T cells, but does not eliminate infectious virus primarily located in monocytes and memory CD4 T cells. Antibodies to HIV-1 are formed but these neither clear the infection nor are protective.

- Acute illness- “flu-like”
- Clinical asymptomatic phase- 2-12 or more years

Second Phase: HIV-1 escapes the CD8 T cell response and mutations in the viral envelope now favor infection and destruction of naive CD4 T cells.

Acquired immune deficiency (AIDS) appears upon depletion of critical CD4 T cell subsets.
Immune response to HIV-1 and effects of HIV infection

CD4 T cells #/μl

CLINICAL
Flu-like Illness
Asymptomatic phase
Symptomatic phase AIDS
Chronic lymphadenopathy
“Set Point”
Mucous membrane Infections, etc.
Host - Parasite Relationships of HIV

Reverse transcriptase has no proofreading function and creates a vast number of mutations

HIV must adapt and evolve in an environment determined by attributes of the host’s immune system

- MHC alleles
- TCR repertoire
- Polymorphism of viral entry receptors
- Chemokine and cytokine milieu (e.g. parasitic infections)
- Other genes regulating immune response
- Prior immune history
- Age

Outcome of infection depends on biology of host, especially whether immune response targets critical HIV structures and HIV-1 mutational capacity, etc.
### HIV-1 genomically highly diverse

**HIV-1**
- HIV-1/U455: Human
- HIV-1/AI: Human
- HIV-1/ELE: Human
- HIV-1/YBF30: Human
- SIVcpzUS: Chimpanzee
- SIVcpzCAM3: Chimpanzee
- SIVcpzGAB1: Chimpanzee
- HIV-1/MPV180: Human
- HIV-1/ANT70: Human
- SIVcpzANT: Chimpanzee

**HIV-2**
- SIVbabe: L'Hoest monkey
- SIVsph: Sun-tailed monkey
- SIVfmc: Mandrill
- SIVagm: African green monkey
- SIVagmVer78: African green monkey
- SIVagmOru77: African green monkey
- SIVagmTen1: African green monkey

**Phylogenetic relationships**
- **A**
- **B**
- **C**
- **D**
- **E**

**Events**
- 1900: US B/C isolate
- 1900 (1931-1942): M Group
- 1938: B/D

**Timeline**
- 1850
- 1900
- 1950
- 2000
- 2050
Cellular Specificity, “Tropism” of HIV strains

Based on envelope structure

• The viral envelope contains sequences that interact with a membrane viral receptor complex composed of CD4 and one of several chemokine receptors

• The sequence of a given viral envelope is specific for one of the chemokine receptor types

• The main two chemokine receptors are CCR5 and CXCR4 that are distributed on different cell lineages

• Strains that bind to CCR5 are termed “R5” tropic and those that bind CXCR4 are termed “R4” tropic
Chemokine Receptors:

**CCR5**

- **Ligands:** RANTES, MIP-1α, MIP-1β are inflammatory cytokines made by *activated CD8* and CD4 T cells in the immune response to HIV and compete with R5 HIV binding to membrane receptor complex, blocking progress of the infection.

- **Distribution:** CCR5 found on monocytes, DC and effector, memory or activated T cells, not naïve CD4 T cells.

- **Biology:** CCR5 responsible for migration of memory and effector T cells, monocytes and dendritic cells to sites of inflammation.

- **Several CCR5 polymorphisms:** e.g. **Δ32 mutant** allele render CCR5 unexpressed and incapable of binding HIV R5 strains.

- **Δ32** Homozygote frequency 1%, heterozygote ~10% in N.European Caucasoids, but X4 strains are still infective.
Chemokine Receptors: Coreceptors for HIV entry

**CXCR4**

- **Ligand:** Stromal derived growth factor 1 (SDF-1) produced by stromal cells. Competes with HIV binding, but not produced in inflammation or by T cells
- **Receptor:** expressed on monocytes, naïve T-cells, B-cells, etc. X4 virus preferentially infects naïve/activated T cells
- **Biology:** SDF-1/CXCR4 responsible for migration/homing of naïve T cells to lymph node
HIV strain tropism early in infection

• *R5 is almost always the sexually transmissible form of the virus*

• Primary isolates from newly infected individuals are usually R5

• R5 strains mainly replicate in monocytes. Activated and memory T cells are infected, but at lower efficiency

• Much of the viral load in earlier phase of HIV infection is in the monocytes and macrophages and the number of CD4 T cells though decreased, remains stable
Mutation of R5 to X4: a few changes in envelope V3 Loop sequence changes strain tropism

Strain (SF162) certain amino acids confer R5 tropism on V3 loop

Strain (SF2) exhibits X4 tropism via binding to CXCR4

Negative to positive charge

R5 → X4
**Evolution of tropism** in an individual from R5 to X4 is the precursor to developing immune deficiency, but R5 strains are preferentially sexually transmitted.

- **Infection by R5 strain**
  - Clinical latency 2-15 years
  - R5 strain

- **Sexual transmission**
  - **Mutation to X4 strain → naïve T cell**
  - X4 strain

- **Infection by R5 strain**
  - Loss of the “epitope war”
  - Loss of ability to control viral replication
  - → AIDS
Acute HIV-1 Infection "Flu-Like"

Clinical
- Headache, retro-orbital pain, myalgias, pharyngitis, fever,
  Nonpruritic maculopapular rash in first 1-3 weeks
  Adenopathy and malaise may last for several months
- Transient thrombocytopenia and CD4 T-cell lymphopenia

Viral
- Rapid appearance of marked viremia with an R5 strain infecting monocytes and memory CD4 T cells
- This results in acute CD4 T-cell lymphopenia
- Integration in memory CD4 T cells provides a long-lived reservoir where HIV can remain latent
- Structurally the initial virus strain has no, or very limited diversity
Acute Infection

Development of anti HIV Immune Response

- With onset of a **CD8 T-cell immune response**, viremia falls from ~5x10^6 /ml to <10^4 /ml
- The CD4 T-cell count rises from ~400 to >800/μl
- Degree of viral suppression and return of CD4 T cell levels (**set point**) varies and correlates with the length of the asymptomatic period
- HIV species begin to **diversify**, viral variants appear reflecting successful attempts to escape the suppression of the CD8 T cell response
CD8 T-cell Response to HIV-1

• Establishes asymptomatic phase of infection

• Specific CD8 CTL lysis of HIV-infected cells via perforin pathway and/or apoptosis via upregulation of fas ligand

• Strong inhibition of viral infectivity by release of chemokines (MIP-1α/β, RANTES) that bind to CCR5 and compete with coreceptor dependent entry of R5 HIV-1

• Release of IFN-γ and secondarily TNF-α, decrease LTR-driven transcription
Excessive anti HIV CD8 T cell response may result in diffuse infiltrative lymphocytosis syndrome (DILS) simulating Sjogren’s syndrome

Salivary gland biopsy

CT scan
CD8 T cells >2000/μl

Nuclide scan

H & E
HLA-DR stain
DILS is usually associated with long term non progression and a favorable outlook

However, it is also associated with a type of B cell lymphoma that occurs early in the course of HIV infection, reflecting chronic B cell stimulation
Anti-HIV antibodies usually appear in several weeks, they play a minor role

Variants emerge too quickly for effective *in vivo* antibody neutralization

Other mechanisms
Immune Responses in asymptomatic phase

Depends on a relatively few CD8 T cell clones

• Maintenance of a few CD8 T-cell expanded memory/effector CTL clones, each comprising 1-5% of CD8 T cell repertoire

• Clones each recognize different immunodominant HIV peptides, great individual variation in number and particular peptide recognized

• More clones = generally good outlook for long asymptomatic period (>12yrs), fewer clones = rapid progression of HIV infection (<2yrs)
Long term non progressors

- A subset of infected individuals that remain asymptomatic for >12 years
- Low levels of plasma virions, CD4 counts >500/μl
- High CD8 T-cell counts, may be > 3,000/μl
- High chemokine release (RANTES, MIP)
- CTL response is against critical conserved region of HIV gag, env, pol that cannot readily be mutated without loss of viral function - The key factor!

- Particular HLA types, e.g. HLA-B27, B57, etc.
The environment formed by peptide binding properties of MHC molecules influences evolution of the HIV infection. HLA alleles influence the number of peptides in a protein that can be recognized (Example HIV envelope protein).

<table>
<thead>
<tr>
<th>Allele:</th>
<th>HLA-B*27052</th>
<th>HLA-B*3501</th>
<th>HLA-B*0702</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motif</td>
<td>XRXYYYYYY[KRYL]</td>
<td>XYYYYYYY</td>
<td>XYYYYYYYYL</td>
</tr>
</tbody>
</table>

Peptides able to bind each allelic molecule:

<table>
<thead>
<tr>
<th>Peptide</th>
<th>HLA-B*27052</th>
<th>HLA-B*3501</th>
<th>HLA-B*0702</th>
</tr>
</thead>
<tbody>
<tr>
<td>RGVQKEY</td>
<td>KRRVQREK</td>
<td>DPNPQEVL</td>
<td></td>
</tr>
<tr>
<td>RPVSTQL</td>
<td>AR LAVERY</td>
<td>KPCVKTLP</td>
<td>KPVVSTQL</td>
</tr>
<tr>
<td>TPNNTK</td>
<td>ERDRDRSI R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QRGPR</td>
<td>LRSCLFSY</td>
<td>SPLSFQTHL</td>
<td></td>
</tr>
<tr>
<td>RAKWNNTL</td>
<td>TR VELLGR</td>
<td></td>
<td>PRRI RQGL</td>
</tr>
<tr>
<td>QFGNK</td>
<td>CRH PR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RGGDMR</td>
<td>RQGLERL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSELYKYK</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

# of peptides: 15, 0, 6
Role of MHC in Recognition of HIV peptides

Rapid HIV progression in HLA-B35 individuals
Viral Response near end of asymptomatic period

• Rate of cellular infection and potential mutations increases

• Definitive viral escape occurs when virus is no longer presented by MHC to available CD8 T cell clones

• Continual generation of env mutations

• Selection against R5 variants by CD8 T-cell CCR5 chemokines that blocks infection is finally bypassed

• Change in cellular tropism by env mutations leads to X4 phenotype (CXCR4, T-tropic)

• Enhanced T-tropism of X4 leads to more significant impairment of CD4 T-cell compartment

Loss of the “epitope war”
Reasons for CD4 T cell loss in HIV-1 Infection

During asymptomatic phase and transition to AIDS

Accelerated loss in number of CD4 T cells

- Activation of large numbers of mature and naïve CD4 T cells by cytokines, etc. during antiviral response (Bystander activation, homeostatic regulation) leads to loss of repertoire by physiologic apoptosis
- Thymic derangement results in failure to generate new naïve CD4 T cells to repopulate repertoire
- CD8 T cell killing of infected CD4 T cells
- ADCC by NK cells, etc. to infected CD4 T cells
Another reason for CD4 T cell loss

CD4 T cell activation initiates HIV replication

T cell activation causes, among other effects, a marked increase in cyclin T1, NFAT and NFκB

This links viral expression to T cell activation, resulting in viral pathogenic effect
AIDS is the consequence of progressive CD4 loss

T cell immune function progressively deteriorates reflecting the central role of CD4 T cells

Stages:

• Loss of antigen-specific clonal responses (in vitro proliferation and skin test to various antigens, including those from immunizations
• Loss of ability to generate new CD8 T cell responses
• Loss of Mixed Lymphocyte Culture responsiveness
• Loss of PHA responsiveness
AIDS is the consequence of progressive CD4 loss

Appearance of different infections as severity of immune deficiency increases

Candida (Thrush)
Salmonella - microbial persistence
Mycobacterium tuberculosis reactivation, Cryptosporidium

Activation of latent herpes zoster

EBV reactivation and development of polyclonal immunoblastic lymphomas, Kaposi’s sarcoma (HHV-8)

Pneumocystis carinii

Progressive cytomegalovirus infections, M. avium complex
HIV virus vaccines have failed, Why?

- Immunization with rENV produce anti HIV antibodies
- But antibodies induced by immunization fail to protect as shown in multiple trials
- A live attenuated virus has not yet proved achievable
- But....
  
  Recombinant “live” viral vector vaccines with portions of the HIV genome produce some CD8 immunity

Heterogeneity of HIV strains: need many immunodominant peptides from critical regions of viral genome for different MHC types because no cross protection (Think Zinkernagel-Doherty experiment)
Case Report of immunity but no protection by a recombinant live vaccine

Betts et al. PNAS 2005, 102:4512

Case # 202-T07, an HLA-B*2705 HIV-negative male homosexual

vCP205 recombinant live virus canarypox vector expressing gp41, Gag and Protease given over 5 months

Immune response documented to two CD8 epitopes and one CD4 epitope including response to the HLA-B*2705-restricted Gag peptide KRWIILGLNK in memory/effector CD8 T cells

Approximately 18 months later 202-T07 had unprotected anal intercourse with an HIV+ partner
Shortly thereafter, he developed flu-like symptoms and was then found to be positive for HIV antibodies, plasma viral load, 235,000 HIV-1 virions/ml.

The acute infection induced a recall response to the B*2705-restricted clone, expanding it from 0.05% of CD8 T cells to 9.8% of CD8 T cells, and this remained the dominant clonotype during acute infection.

By 32 months after diagnosis the predominant virion-encoded Gag peptide sequence mutated from KRWIIIGLNK to KGWIIIGLNK, thus thwarting binding and presentation of the peptide by HLA-B*2705.

His CD4 T cell count continues to decline, presently 400 cells/μl at 32 months post infection, and viral titre remains high, despite anti-retroviral therapy.
Viral escape at 32 months is extremely unusual, the average time to development of this escape mutation in unvaccinated individuals is >9 years

*The average survival until AIDS in an HLA-B*2705 individual is >14 years*

*The authors raise the strong possibility that a vaccine developed according to the best notions of current immunological knowledge not only did not protect against HIV infection but accelerated development of the escape mutation in the vaccinated individual, thus hastening progression of the viral infection*
November 2007

Another failed trial

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

(Based on an interim data review, the DSMB concluded that the vaccine cannot be shown in this trial to prevent HIV infection or affect the course of the disease.)

Sponsors and Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
HIV Vaccine Trials Network

Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)

ClinicalTrials.gov Identifier: NCT00486408

Purpose

The purpose of this study is to intensively characterize the immune response, particularly the T-cell response, to a three-dose regimen of an adenovirus-based HIV-1 vaccine in HIV-uninfected adults.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Infections</td>
<td>Biological: MRKAd5 HIV-1 gag/pol/nef</td>
<td>Phase I</td>
</tr>
</tbody>
</table>

MedlinePlus related topics: AIDS
Merck AIDS Failure Hurts Global HIV Vaccine Research (Update1)

By John Lauerman

Nov. 15 (Bloomberg) -- The surprise failure of Merck & Co.'s AIDS vaccine may doom other test projects and force researchers to consider whether a protective shot against HIV is feasible.

Merck halted clinical trials of its vaccine in September, and last week researchers said that a cold virus used in the shot made test subjects more likely to catch HIV. The finding may cause the U.S. to cancel a study of a similar vaccine and raises concern about projects at Crucell NV.

The Merck setback means that 25 years into the AIDS epidemic doctors are still far from having a protective vaccine. An international team of scientists has been recruited to determine precisely what went wrong. Meanwhile, leading researchers are re-examining their vaccine strategies, said David Ho, who has studied HIV since the epidemic began.

"It's a giant step backwards," Ho, scientific director of the Aaron Diamond AIDS Research Center in New York, said in a telephone interview. "It calls into question all the vaccines using related strategies that have been leading the field."
Merck vaccine candidate (V520) for CD8 immunity

- adenovirus type 5 vector containing gag, pol and nef

- 3,000 HIV-negative volunteers at high risk of HIV infection

- The vaccine did not prevent infection
  - 19 developed HIV / 672 vaccinated
  - 11 developed HIV / 691 placebo control

- And did not reduce the amount of virus in the blood of those who became infected
  - 40,000 copies/ml in vaccine group
  - 37,000 copies/ml in placebo group
Hope?

Sept 24, 2009 New NIH/US Army trial

“Risk of infection had been cut by 31.2 percent”

Vaccine combination of two that failed

• ALVAC, a canary pox “live” vaccine
• AIDSVAX, gp120 r ENV

16,402 volunteers in Thailand

74 infections in placebo group
51 in vaccine group
But no diminution in viral levels or CD4 drop in those infected